Sugi Predict

Sugi Predict / Compounds / SCHEMBL783487

SCHEMBL783487

SCHEMBL783487

Cn1c(=O)oc2ccc(-c3cncc(CO)c3)cc21

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KCNJ1 P48048 6/20 0.51
▸ CYP11B2 P19099 3/20 0.50
▸ CYP11B1 P15538 2/20 0.45
▸ GPR55 Q9Y2T6 2/20 0.43
▸ PRMT5 O14744 1/20 0.41
▸ WDR77 Q9BQA1 1/20 0.41
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ GRK2 P25098 1/20 0.38
▸ CLK1 P49759 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.38
▸ TNIK Q9UKE5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL782500 0.90 KCNJ1 (0.50) KCNJ1CYP11B2GPR55PDE10ATNIK
SCHEMBL783194 0.82 KCNJ1 (0.58) KCNJ1CYP11B2GPR55TNIK
SCHEMBL783483 0.81 KCNJ1 (0.53) KCNJ1CYP11B2CYP11B1GPR55
SCHEMBL801469 0.81 GPR55 (0.54) KCNJ1CYP11B2CYP11B1GPR55
SCHEMBL783485 0.80 CYP11B2 (0.43) KCNJ1CYP11B2CYP11B1GPR55PDE10A
SCHEMBL782302 0.80 CYP11B2 (0.40) KCNJ1CYP11B2CYP11B1PDE10A
SCHEMBL783335 0.79 KCNJ1 (0.46) KCNJ1CYP11B2
SCHEMBL782587 0.79 CYP11B2 (0.52) KCNJ1CYP11B2CYP11B1GPR55
SCHEMBL782371 0.79 CYP11B2 (0.64) KCNJ1CYP11B2CYP11B1GPR55
SCHEMBL783358 0.79 CYP11B2 (0.49) KCNJ1CYP11B2CYP11B1GPR55PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 — — EP disclosed
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 — — EP disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS CYP11B2, CYP11B1, CYP21A2 KCNJ1 630/4885CYP11B2 1/4885CYP11B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.